Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil dosage in percutaneous vertebroplasty
NCT05876039Phase 4Completed
- Sponsor
- Tri-Service General Hospital
- Start
- May 2023
- Primary completion
- Aug 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised trial of remifentanil in Vertebral fracture, sponsored by Tri-Service General Hospital. Primary endpoints: Adequate analgesia at the time of the trocar needle insertion and Adequate analgesia at the time of the bone cement injection. Started May 2023; status: completed.
02
Drugs
remifentanil
03
Conditions
Vertebral fracture
Beyond the preview
Go deeper on NCT05876039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05876039.